Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVV-IL-2
- Development stage
- Preclinical
- Modality
- Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraperitoneal
01
Overview
RVV-IL-2 is a recombinant vaccinia virus (rVV) engineered to encode or deliver interleukin-2 (IL-2), intended to augment antitumor immune responses by combining the immunogenic properties of a viral vector with the immunostimulatory effects of IL-2. The mechanism involves both direct presentation of tumor-associated antigens (TAAs) via the viral vector and immune cell expansion/activation by IL-2, with demonstrated effects in experimental cancer models of reducing metastases and prolonging survival when administered with tumor antigen-expressing rVV. IL-2 functions as a cytokine to stimulate T cell and natural killer cell proliferation and activation. This combination strategy is used primarily in cancer immunotherapy research to enhance cytotoxic lymphocyte responses, and may be constructed for gene therapy approaches or as an adjuvant to cancer vaccines[1][6].
- Other names
- RVV-IL-2RVV-IL2RVV-IL 2
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RG (Interleukin-2 receptor gamma subunit)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on RVV-IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVV-IL-2.